Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lack of Vitamin D may be linked to dementia

This article was originally published in The Tan Sheet

Executive Summary

Researchers should investigate whether vitamin D deficiency is linked to Alzheimer's disease, says William Grant of the Sunlight, Nutrition and Health Research Center. He explains in the May 2009 issue of the Journal of Alzheimer's Disease that low serum levels of 25-hydroxyvitamin D are associated with cardiovascular disease, diabetes and oral health - all of which are risk factors for or precede dementia

You may also be interested in...



NIST offers Vitamin D SRM

The National Institute of Standards and Technology offers a new standard reference material, SRM 972, for vitamin D in human serum. The material will help labs more accurately measure patients' vitamin D levels so physicians can diagnose accurately when people are deficient, NIST said. It added physicians are testing vitamin D levels more in part because recent studies link low levels of vitamin D to increased risk of certain diseases (1"The Tan Sheet" June 1, 2009)

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel